News

News

 

Latest news

XNK Therapeutics appoints Michael Uhlin as Chief Scientific Officer

XNK Therapeutics appoints Dr. Johan Aschan as Chief Medical Officer

XNK Therapeutics completes private placement of SEK 64 million

Resolution from extraordinary general meeting in XNK Therapeutics

XNK partners with KI on Phase II study in MM with support from Sanofi

2020


XNK Therapeutics partners with Cellect for next generation platform development

XNK Therapeutics receives US orphan drug status

Resolutions from extraordinary general meeting in XNK Therapeutics

XNK Therapeutics appoints Stephan Meinke as Head of R&D

First results from the ACP-001 study presented at EHA

XNK Therapeutics appoints Hans Ericson as CFO

XNK Therapeutics appoints Johan Liwing as CEO

XNK Therapeutics joins Vinnova’s NextGenNK competence center

2019


XNK patent for expansion of NK cells validated in 18 European countries

XNK Therapeutics patent for expansion of NK cells granted in Japan

XNK patent for expansion of NK cells granted in Europe

2018


XNK Therapeutics granted SEK1m by Sweden’s Vinnova

XNK Therapeutics’ patent for expansion of NK cells granted in Korea

XNK Therapeutics becomes a partner in Swelife’s health economics project

Agneta Edberg appointed to board of XNK Therapeutics

XNK Therapeutics granted SEK1m by Sweden’s Vinnova to partner in AdBIOPRO

2017


XNK Therapeutics receives orphan drug designation from EMA

XNK Therapeutics granted US patent for method to treat MM with NK cells